Neuropathic pain is a distressing sensory and emotional behaviour which traced back to real or imagined tissue injury. In a seminal study published in 1938, English neurologist George Riddoch said that pain is experienced only intermittently in the life of the healthy, its neural mechanisms lying dormant, but vigilant, ready to be awakened if the tissues of the body are threatened. The present review was based on the literature survey of pregabalin’s effectiveness in different types of neuropathic pain. In some countries, like the UK, France, and Austria, the rates are as high as 8%, 6.9%, and 3.3%, respectively. Pregabalin (3-(aminomethyl)-5-methylhexanoic acid) is another synthetic atom and an underlying structure of the inhibitory junction (neurons) γ-aminobutyric corrosive. It is a α2- δ ligand having pain relieving, anti-convulsant, anxiolytic, and rest adjusting exercises. Pregabalin exhibits inhibitory effect on the release of Sub-P, CGRP and glutamate thus subsides neuropathic pain perception. Strong opioids, non-gabapentinoid antiepileptic medications, and cannabinoids are frequently prescribed as third- and fourth-line medications. In general, bigger doses of pregabalin lead to worse poisonings. Below 20mg/kg, most people (83%) only have slight poisoning if they take less than 20mg/kg. It concluded that pregabalin has been extensively utilized as effective drug against neuropathic pain generated due to various medical conditions including chronic diabetes, cancer neuropathy, fibromyalgia, trigeminal neuralgia, post-herpetic neuralgia and spine diseases or damages. It is also regarded as safe moiety for the treatment of neuropathic pain.